Pre-Exposure Prophylaxis (PrEP)

PreclinicalSmall molecule

Pre-Exposure Prophylaxis (PrEP) is one of 3 small molecule programs targeting HIV Prevention. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV PreventionCompleted

HIV PreventionPreclinical

Completed

Competition

Competitive Landscape

4 competitors in HIV Prevention

#DrugCompanyPhaseTrials

Alhydrogel Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 2

GLA-SE Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 3

Pre-Exposure Prophylaxis (PrEP)

NNew York University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV Prevention1 trial

Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)

Completed·NNew York University·N/A·NCT01571128·1,215 enrolled

HIV infection1 trial

Integrating PrEP Into Mobile Addiction and Primary Care Services (MAPS)

Completed·DDuke University·Approved·NCT06908252·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pre-Exposure Prophylaxis (PrEP). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pre-Exposure Prophylaxis (PrEP) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pre-Exposure Prophylaxis (PrEP). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNew York University

Pre-Exposure Prophylaxis (PrEP)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV Prevention1 trial

HIV infection1 trial

References

Drug Info

Quick Facts

Related News